srch

This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by ...

Using its powerful Insights-to-Validation Platform and proprietary chemical library, Blueprint Medicines is working to develop new therapeutic compounds and combination Lists Featuring This Company Medical Companies (Top 10K) 9,875 Number of Organizations • $344.6B Total Funding Amount • 25,179 Number of Investors

The Investor Relations website contains information about Blueprint Medicines Corp.'s business for stockholders, potential investors, and financial analysts.

BPMC Blueprint Medicines 10-K2020 FY Annual report · (1), Registration Statement (Form S-3ASR No. 333-236424) of Blueprint Medicines Corporation, · (2) ...

Transformative science, targeted medicines ... We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better ...

Blueprint Medicines Corp Banner Image ... Blueprint Medicines Corporation, a biopharmaceutical company, ... MOST RECENT 2020 Annual Report and Form 10K.

18.02.2021 · Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results -- Supplemental NDA accepted by FDA for AYVAKIT™ (avapritinib) for advanced systemic mastocytosis---- Type II variation MAA submitted to EMA for AYVAKYT® (avapritinib) for advanced systemic mastocytosis---- Announced a potential best-in-class research program …

Blueprint Medicines Announces Pricing of Public Offering of Shares of ... in the section entitled “Risk Factors” in Blueprint Medicines' Annual Report on ...

Blueprint Medicines Corp. SEC filings breakout by MarketWatch. View the BPMC U.S. Securities and Exchange Commission reporting information.

Blueprint Medicines Appoints Daniella Beckman to its Board of Directors Dec 07, 2021 Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) More News Events and presentations Nov 29, 2021 Blueprint Medicines Conference Call Oct 28, 2021 Q3 2021 Blueprint Medicines Corp Conference Call More events and presentations

PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today ... including Blueprint Medicines' most recent Annual Report on Form 10-K ...

Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company’s lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic ...

102 rader · 29.10.2021 · Blueprint Medicines (Issuer) Form 4. Statement of changes in …

Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Blueprint Medicines Corp (BPMC) using our online tools.